Superworth

Hemab Therapeutics COAG

Biotechnology, Healthcare
$41.18
−0.65%
Market cap
$1.9B
PE
n/m
one or more of the four quarters through 2026-06-30 missing
Forward PE
n/m
not a meaningful number
Price to sales
n/m
not a meaningful number
EV/EBIT
n/m
not a meaningful number
Revenue, 12 months
n/m
not a meaningful number
Net margin
n/m
not a meaningful number
Free cash flow yield
n/m
not a meaningful number

Charts

Financials

Income statement for COAG, by quarter
Income statementQ1 FY25Q2 FY25Q1 FY26Q2 FY26
R&D$14.1M$12.9M$19.5M$20.3M
SG&A$2.5M$3.2M$4.2M$5.7M
−$16.6M−$16.1M−$23.6M−$26.1M
Pre-tax income−$15.5M−$12.2M−$22.7M−$24.1M
−$190K$4K$12K$97K
Net income−$15.3M−$12.2M−$22.7M−$24.1M
−$16.18−$12.91−$23.98−$0.80
946K946K946K30.1M

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Biotechnology nearest Hemab Therapeutics' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
COAGHemab Therapeutics$1.9Bn/mn/an/mn/mn/m
VCELVericel$2.1B88.1×157×6.8×+23%7.9%
ADMAAdma Biologics$2.5B15.8×21.3×4.8×+8%33.0%
MGTXMeiraGTx$895.1M13.1×15.4×2.3×n/m19.9%
KRYSKrystal Biotech$8.8B37.1×42.5×19.9×+23%54.8%
RGENRepligen$9.8B237×123×12.4×+16%5.3%
TECHBIO-TECHNE$11.4B63.2×62.0×9.4×−0%15.0%
HALOHalozyme Therapeutics$14.6B38.5×21.3×8.8×+41%24.9%
NBIXNeurocrine Biosciences$14.8B21.3×42.6×4.4×+34%20.9%
EXELExelixis$17.4B22.1×22.7×7.1×+9%35.3%
PLXProtalix BioTherapeutics$206.3M11.1×33.6×2.6×+30%23.5%
Peer median$9.3B29.6×38.1×7.0×+23%22.2%

More on Hemab Therapeutics

Each number over time

Its groups

About

Industry
Biotechnology
Sector
Healthcare

Valuation data, not investment advice. Prices as of .